|
Published by: Urch Publishing
Published: Apr. 1, 1999 - 191 Pages
Table of Contents
Executive Summary
Chapter 1: Market And Technology Overview
- Introduction and scope
- A primer on DNA, RNA and the mechanism of antisense action
- Therapeutic applications of antisense
- Review of oligonucleotide chemistries
- First-generation oligonucleotides
- Second-generation oligonucleotides
- Third-generation oligonucleotides
- Novel types of oligonucleotide
- Gene-targeting oligonucleotides
- Protein-targeting oligonucleotides
- Ribozymes and other catalytic oligonucleotides
- Delivery of oligonucleotides
- Enhancement of stability and cellular uptake
- Targeted delivery
- Noninvasive delivery
- Antisense oligonucleotides under commercial investigation
- Highlights from clinical trials
- Three generations of antisense products
- Various antisense oligonucleotides
- Other oligonucleotides under commercial investigation
- Oligonucleotides with antiviral properties
- Oligonucleotides with specific properties
- Protein-binding oligonucleotides
Chapter 2: Company Profiles
- List of companies profiled
- Amgen Inc.
- Angiogene Inc.
- Antisoma PLC
- Aronex Pharmaceuticals Inc.
- Atlantic Pharmaceuticals Inc.
- AVI BioPharma Inc.
- Baxter International
- BioResearch Ireland
- Biovector Therapeutics SA
- Boehringer Ingelheim GmbH
- Boron Biologicals Inc.
- Bristol-Myers Squibb Company
- Chemo-Sero-Therapeutic Research Institute
- Chiron Corporation
- Chugai Pharmaceutical Company Ltd
- Crinos Industria Farmacobiologica SPA
- Cryogenic Solutions Inc.
- CV Therapeutics Inc.
- DanBioSyst UK Ltd
- DepoTech Corporation
- Epoch Pharmaceuticals Inc.
- GeneSense Technologies Inc.
- Genset
- Genta Inc.
- Genzyme Corporation
- Geron Corporation
- Gilead Sciences Inc.
- Glaxo Wellcome PLC
- Hesed Biomed Inc.
- Hoechst AG
- Human Genome Sciences Inc.
- Hybridon Inc.
- ICN Pharmaceuticals Inc.
- Immune Response Corporation
- Incyte Pharmaceuticals Inc.
- Inex Pharmaceuticals Corporation
- Inkine Pharmaceutical Company Inc.
- Innovir Laboratories Inc.
- Intercardia Inc.
- Iomed Inc.
- Isis Pharmaceuticals Inc.
- Kimeragen Inc.
- Lynx Therapeutics Inc.
- Medtronic
- Methyl-Gene Inc.
- NeoPharm Inc.
- NeXstar Pharmaceuticals Inc.
- Novartis AG
- NovoPharm Biotech Inc.
- Oligo Therapeutics Inc.
- Oncor Inc.
- Pantheco A/S
- Ribozyme Pharmaceuticals Inc.
- Sankyo Company Ltd
- Sequus Pharmaceuticals Inc.
- Somagenics Inc.
- SRC VB Vector
- Supratek Pharma Inc.
- Synsorb Biotech Inc.
- Targeted Genetics Corporation
- Theratechnologies Inc.
- Vical Inc.
- VIMRx Pharmaceuticals Inc.
- Zynaxis Inc.
Chapter 3: Financial And Market Analyses
- Markets for oligonucleotide therapeutics
- AIDS and related conditions
- Gastroenterology
- Cancer
- Dermatology
- Immunology
- Musculoskeletal disorders
- Ophthalmology
- Deep vein thrombosis
- Other indications
- Market forecast
- Oligonucleotide company league tables
Chapter 4: Trends And Opportunities
- Antisense therapeutics - an area of opportunity
- Third-generation oligonucleotides - cheaper yet better
- New perspectives in delivery of oligonucleotides
- Prospects for large-scale oligonucleotide synthesis
- Applications of antisense to drug and gene target validation
- Oligonucleotide strategies not based on antisense
- Patent analysis
- Assignee organisations
Terms And Abbreviations
Exchange Rates Used In This Report
List Of Tables
Table 1.1: Oligonucleotide chemistries
Table 1.2: Novel types of oligonucleotide
Table 1.3: Oligonucleotide delivery systems
Table 1.4: Three generations of antisense oligonucleotides
Table 1.5: Antisense oligonucleotides (various)
Table 1.6: Oligonucleotides not based on antisense
Table 2.1: Amgen - financial data 1996-98
Table 2.2: Aronex Pharmaceuticals - financial data 1995-97
Table 2.3: Atlantic Pharmaceuticals - financial data 1996-98
Table 2.4: AVI BioPharma - financial data 1996-97
Table 2.5: Baxter International - financial data 1996-98
Table 2.6: Boehringer Ingelheim - financial data 1996-97
Table 2.7: Bristol-Myers Squibb - financial data 1996-98
Table 2.8: Chemo-Sero-Therapeutic Research Institute - financial information
Table 2.9: Chiron - financial data 1995-97
Table 2.10: Chugai Pharmaceutical - financial data 1996-98
Table 2.11: CV Therapeutics - financial data 1996-97
Table 2.12: Epoch Pharmaceuticals - financial data 1995-97
Table 2.13: Genset - financial data 1996-97
Table 2.14: Genta - financial data 1995-97
Table 2.15: Genzyme - financial data 1995-97
Table 2.16: Geron - financial data 1996-97
Table 2.17: Gilead Sciences - financial data 1996-98
Table 2.18: Glaxo Wellcome - financial data 1995-97
Table 2.19: Hoechst AG - financial data 1997
Table 2.20: Hoechst Marion Roussel - financial data 1996-97
Table 2.21: Human Genome Sciences - financial data 1995-97
Table 2.22: Hybridon - financial data 1995-97
Table 2.23: ICN Pharmaceuticals - financial data 1995-97
Table 2.24: Immune Response - financial data 1995-97
Table 2.25: Incyte Pharmaceuticals - financial data 1995-97
Table 2.26: Inex Pharmaceuticals - financial data 1996-97
Table 2.27: Inkine Pharmaceutical - financial data 1996-98
Table 2.28: Innovir Laboratories - financial data 1995-97
Table 2.29: Intercardia - financial data 1996-98
Table 2.30: Iomed - financial data 1997-98
Table 2.31: Isis Pharmaceuticals - financial data 1995-97
Table 2.32: Lynx Therapeutics - financial data 1997
Table 2.33: Medtronic - financial data 1996-98
Table 2.34: NeoPharm - financial data 1995-97
Table 2.35: NeXstar Pharmaceuticals - financial data 1995-97
Table 2.36: Novartis - financial data 1995-97
Table 2.37: NovoPharm Biotech - financial data 1996-97
Table 2.38: Oncor - financial data 1995-97
Table 2.39: Ribozyme Pharmaceuticals - financial data 1996-97
Table 2.40: Sankyo - financial data 1996-98
Table 2.41: Sequus Pharmaceuticals - financial data 1995-97
Table 2.42: Synsorb Biotech - financial data 1996-97
Table 2.43: Targeted Genetics - financial data 1995-97
Table 2.44: Vical - financial data 1995-97
Table 2.45: VIMRx Pharmaceuticals - financial data 1995-97
Table 3.1: Important clinical indications for oligonucleotide therapy
Table 3.2: World pharmaceutical market by region in 1998
Table 3.3: Sizes of oligonucleotide-related pharmaceutical markets in 1998
Table 3.4: Oligonucleotides in clinical trials
Table 3.5: Oligonucleotide therapeutics market in 1999 and 2005
Table 3.6: Top 35 companies ranked by total revenues
Table 3.7: Top 35 companies ranked by net income/loss
Table 3.8: Top 35 companies ranked by total assets
Table 3.9: Top 35 companies ranked by R&D expenditure
Table 4.1: Oligonucleotide therapeutic patents, by subject
Table 4.2: US patents concerning oligonucleotides targeted at specific genes
Table 4.3: US patents concerning modified oligonucleotides
Table 4.4: US patents concerning oligonucleotide delivery methods
Table 4.5: US oligonucleotide patents concerning general therapeutic methods
Table 4.6: Patenting activity by organisation
Table 4.7: Patent citations by organisation
Table 4.8: Top 10 patent citations in oligonucleotide therapeutics
AbstractNew technological advances in molecular biology have led to the identification of genes associated with major human diseases and to the determination of their genetic basis. Antisense oligonucleotide technology is providing a highly specific strategy for targeting a wide range of diseases at genetic level.
In this rapidly expanding market, the race is on to develop oligonucleotide drugs for the treatment of diseases such as Cancer, HIV, Hepatitis B and a range of inflammatory conditions. This report, part of the Informa Pharmaceuticals BioFrontiers series, reviews commercial activity in the field of therapeutic oligonucleotides.
Key benefits include:
- Provides a comprehensive overview of the technology including tables of First, Second and Third generation oligonucleotides
- Profiles over 63 companies and their subsidiaries active within the Oligonucleotide therapeutic market
- Features 83 product candidates and an analysis of 320 oligonucleotide-related US patents
- Assesses financial, drug patent and market analyses
- Illustrated with company league tables and revenue forecasts to 2005
Get Full Details About This Report >>
|
